AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cytek Biosciences, Inc. Director's Dealing 2021

Jul 23, 2021

32966_dirs_2021-07-22_90201008-ccf5-4953-9270-b56ba0c071f4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cytek BioSciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: Yan Ming (Director, Chief Technology Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8139792	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.25	2027-06-28	Common Stock (62456)		Direct
Stock Option (Right to Buy)	$0.92	2030-07-24	Common Stock (26666)		Direct

Footnotes

F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 24, 2021; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.